• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Significant Cost Savings Associated With Emergence Of Prospective Surveillance Model As Standard Of Care For Breast Cancer Treatment

Article

Early diagnosis and treatment of breast cancer-related lymphedema by a physical therapist can significantly reduce costs and the need for intensive rehabilitation, according to an article published in the January issue of Physical Therapy (PTJ), the scientific journal of the American Physical Therapy Association (APTA).

The study compared a prospective surveillance model with a traditional model of impairment-based care and examined the direct treatment costs associated with each program. Treatment and supply costs were estimated based on the Medicare 2009 physician fee schedule. Researchers estimated that treatment for breast cancer-related lymphedema costs $636.19 a year when the prospective surveillance model was used vs $3,124.92 for traditional treatment of advanced lymphedema.

The goal of a prospective surveillance model for cancer rehabilitation is to identify impairment at the earliest onset to alleviate impairment or prevent it from progressing. Soon after diagnosis, a physical therapist will perform a preoperative examination to establish a baseline level of function. Follow-up examinations are then conducted postoperatively at 1 month and then 3-month intervals, for up to 1 year. In contrast, a traditional model focuses on treating lymphedema once it has progressed and patients already have functional limitations.

"This study begins to paint a picture of evidence showing that prevention of chronic conditions such as lymphedema - using rehabilitation models of care - may result in significant cost savings," said Stout.

Read more at: http://www.medicalnewstoday.com/releases/240040.php

Source: Medical News Today

Related Videos
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.